¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  : 2019-06-01
±³À°ÀÏÀÚ : 2019-06-01
±³À°Àå¼Ò : °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ  
±³À°ÁÖÁ¦ : 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡±  
ÁÖÃÖ±â°ü : °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø
´ã´çÀÚ : ±èµµÈ­
¿¬¶ôó : 02-2258-3005  
À̸ÞÀÏ : hh@cmcnu.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï : Àü¹®ÀÇ-40,000¿ø / Àü°øÀÇ °£È£»ç-20,000¿ø ´çÀϵî·Ï : Àü¹®ÀÇ-50,000¿ø / Àü°øÀÇ °£È£»ç-30,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 09:30~10:20 Registration  () 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:20~10:30 Opening remarks  ±èµ¿¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 10:30~11:00 Minimal residual disease in acute myeloid leukemia and myelodysplastic syndrome  Á¶º´½Ä(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:00~11:30 Biology and Current management for Primary myelofibrosis  ¾ö±â¼º(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 11:30~12:00 Recent updates in management of Plasma cell myeloma  ¾öÇö¼®(±¹¸³¾Ï¼¾ÅÍ) 
½Ä»ç 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 12:00~13:00 ½Ä»ç  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:00~13:40 Strategies to overcome chemotherapy resistance by controlling tumor microenvironment  ÀÌÈ£¿µ(¼­¿ï´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 13:40~14:20 Translational hematology research for aging and cell therapy using non-human primate hematopoietic stem cells  À¯°æ·Ï(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 14:20~15:00 Cell fate determinants in leukemic progression  ±ÇÇõ¿µ(¼øõÇâ´ëÇб³) 
È޽Ġ06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:00~15:15 Coffee break  () 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:15~15:45 Basic Immunology: Harnessing T cells for adoptive cell therapy  ¹ÚÀ±(Çѱ¹°úÇбâ¼ú¿ø) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 15:45~16:15 Future treatment options using CAR-T cell: From Clinician¡¯s Perspective  ÀÌÀç¿í(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:15~16:45 Practical consideration on manufacturing and commercialization of CAR-T and beyond: From an Industrial Perspective  ±è¼¼¿ø(SL-BIGEN) 
±âŸ 06-01 °¡Å縯´ëÇб³ ¼ºÀÇȸ°ü ¸¶¸®¾ÆȦ 16:45~17:00 Closing remarks  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 °¡Å縯Ç÷¾×º´¿ø ½ÉÆ÷Áö¾ö ¡°For a Better Understanding of State-of-the art Concepts in Hematologic Diseases ¡± : 2019-06-01""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2019 (Á÷¼±Á¦)´ëÇÑ»êºÎÀΰúÀÇ»çȸ Àü±¹¼øȸ¼¼¹Ì³ª : 2019-06-01
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø 2019³âµµ ´ëÀü±¤¿ª½ÃÁß±¸,¼­±¸ÀÇ»çȸ Çмú´ëȸ : 2019-06-01
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 961 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,503 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 923 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 760 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 624 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,476 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,539 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 507 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 471 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 785 2018-08-15
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 758 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 803 2018-08-15
420 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦1ȸ ºñ¸¸Àü¹®°¡ ½ÉÈ­°úÁ¤: ºñ¸¸ Àü¹® ÀÎÁ¤ÀÇ ±³À° Part 1. : 2018-09-09 0 579 2018-08-15
419 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø 2018³â Çù·Âº´ÀÇ¿ø ÀÇ»ç ¿¬¼ö°­Á : 2018-09-09 0 1,357 2018-08-15
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷